© 2005-2012 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.
To help doctors give their patients the best possible care, the American Society of Clinical Oncology (ASCO) developed evidence-based recommendations for treatment with hormonal therapy for early-stage breast cancer. In 2002, ASCO developed a clinical practice guideline about the use of aromatase inhibitors for early-stage breast cancer. Since then, this guideline was updated several times based on clinical trials that included aromatase inhibitors for early-stage breast cancer. In 2010, this guideline was further updated to provide guidance on the use of tamoxifen (Nolvadex) and aromatase inhibitors. This guide for patients is based on the most recent ASCO recommendations.
Key Messages:
- Adjuvant hormonal therapy is offered to patients with hormone receptor-positive breast cancer after surgery and/or radiation therapy or chemotherapy to lower the risk of the cancer returning.
- Hormonal therapy options for postmenopausal women (those who have gone through menopause) with hormone receptor-positive breast cancer include aromatase inhibitors and tamoxifen.
- These drugs have different side effects. Women should speak with their doctors about hormonal therapy options, including how long therapy will last, the risks and benefits of the available drugs, and the cost of hormonal therapy.